Naloxone: Policies and Access
Policies have helped make naloxone more available, thus contributing to the reduction of opioid-related deaths in the U.S.
Despite increased attention to opioid abuse in the past few years, opioid use and average daily dose in individuals who are commercially insured and those receiving Medicare have remained relatively ...
Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist.
The new plan will break out the current guidance into 4 separate guidances.